Agomab Appoints Industry Veteran David Epstein as Chairman of its Board of Directors
July 09 2024 - 7:00AM
Business Wire
Agomab Therapeutics NV (‘Agomab’) today announced that it has
appointed David Epstein as non-executive board member and Chairman
of its Board of Directors.
David is an industry veteran and most recently served as
Seagen’s Chief Executive Officer and as a member of its Board of
Directors. Under his leadership, Seagen significantly grew its
portfolio of innovative cancer medicines and was acquired for more
than $43 billion by Pfizer in December 2023. Prior to Seagen, he
served as Novartis Pharmaceuticals’ Chief Executive Officer. David
has more than 30 years of drug development, deal-making,
commercialization and leadership experience on a global scale. Over
the course of his career, he has led the development and
commercialization of over 30 new molecular entities, including
Glivec, Tasigna, Gilenya, Cosentyx, Entresto and Padcev. He was
named by FierceBiotech as one of the “25 most influential people in
biopharma”.
“We are very happy to welcome David as Chairman of our Board of
Directors. David serves as a role model in the industry and we look
forward to working closely with him and leveraging his experience
to help bring innovative treatments to patients with fibrotic
diseases,” said Tim Knotnerus, Chief Executive Officer of
Agomab. “I want to thank John Haurum for his dedication,
leadership, and valuable insights as our previous Chair. John led
Agomab’s Board during a transformational period for the company,
with multiple successful financing rounds, the acquisition of Origo
Biopharma and the progress from a preclinical to a clinical-stage
company.”
“I am very impressed by Agomab’s science and strategy and I look
forward to working with Tim and his team in bringing Agomab to the
next phase of development and growth,” said David Epstein,
Chairman of Agomab’s Board of Directors. “Fibrotic diseases
represent a serious unmet medical need and I truly believe Agomab’s
approach could represent great strides for patients with
Fibrostenosing Crohn’s Disease and Idiopathic Pulmonary Fibrosis,
if approved.”
About Agomab
Agomab is focused on achieving disease modification by
modulating fibrosis and regeneration in chronic indications such as
Fibrostenosing Crohn’s Disease and Idiopathic Pulmonary Fibrosis.
We do this by targeting biologically validated pathways - including
Transforming Growth Factor β and Hepatocyte Growth Factor - and by
applying specialized capabilities in organ-restricted small
molecules and high affinity antibodies. With a differentiated
clinical pipeline across several fibrotic disorders, end-to-end
research and development capabilities, a proven BD track-record and
a strong investor base, Agomab is building a leading biopharma
company.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240709638104/en/
For Agomab Therapeutics Tim Knotnerus, CEO E-Mail:
tim.knotnerus@agomab.com Media Requests for Agomab Dr.
Stephanie May or Gretchen Schweitzer Trophic Communications Phone:
+ 49 (0) 172 861 8540 E-Mail: agomab@trophic.eu